Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTA: Aerosolized Albuterol in Acute Lung Injury
NCT00434993Phase 3Terminated
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2007
- Primary completion
- Sep 2008
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of albuterol dry powder inhaler in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Ventilator Free Days at 28 days. Started Aug 2007; status: terminated.
02
Drugs
albuterol dry powder inhaler
03
Conditions
acute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT00434993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00434993.